Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease

Autor: Sandler, R. S., Long, M. D., Kappelman, M. D., Martin, C.

Patients with inflammatory bowel disease (IBD) on certain immunosuppressants have increased herpes zoster (HZ) risk.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a40f12d00a315035592286ce2221b677

Improved Outcomes in a Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease

Autor: Crandall, W. V., Kappelman, M. D., Boyle, B. M., Leibowitz, I., Duffy, L. F., Grunow, J. E., Schoen, B. T., Colletti, R. B., Pratt, J. M., Margolis, P. A., King, E. C., Kim, S. C.

Unintended variation in the care of patients with Crohn disease (CD) and ulcerative colitis (UC) may prevent achievement of optimal outcomes. We sought to improve chronic care delivery and outcomes for children with inflammatory bowel disease by usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4ecf5304d9292abb0adbd1c6aa6dba2

Development and validation of the TUMMY-UC, a patient-reported outcome in paediatric ulcerative colitis: a multicenter prospective study.

Autor: Turner, D., Marcovitch, L., Focht, G., Carmon, N., Tersigni, C., Ledder, O., Lev Tzion, R., Frost, K., Church, P. C., Baldassano, R., Otley, A., Kappelman, M. D., Griffiths, A. M.

Publikováno v: Journal of Pediatric Gastroenterology & Nutrition; 2022 Supplement, Vol. 74, p605-606, 2p

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Autor: Ryan C. Ungaro, Therapy Psoriasis Patient Registry for Outcomes, Leanna Wise, Hanns-Martin Lorenz, Pascal Claudepierre, Suleman Bhana, Michael D. Kappelman, Anja Strangfeld, Loreto Carmona, Wendy Costello, Eva Klingberg, Elsa F Mateus, Pedro Machado, Rosana Quintana, Jeffrey A. Sparks, Mark Yates, Zara Izadi, Erica J. Brenner, Nick Dand, Jean W. Liew, Bimba F. Hoyer, Gabriela Schmajuk, Alí Duarte-García, Carolina A. Isnardi, Saskia Lawson-Tovey, Kristin M. D’Silva, Patricia P. Katz, Manasi Agrawal, Jinoos Yazdany, Philippe Goupille, Zenas Z N Yiu, Zachary S. Wallace, Enrique R. Soriano, Catherine H. Smith, Ana Rita Cruz-Machado, Emily L Gilbert, Naomi J Patel, Maria O Valenzuela-Almada, Jonathan S. Hausmann, Christopher E.M. Griffiths, Giovanna Cuomo, Emily Sirotich, Stephanie Rush, Laura Trupin, Ana Carolina Mazeda Pereira, Xian Zhang, Kimme L. Hyrich, Jean-Frederic Colombel, René-Marc Flipo, Rebecca Hasseli, Alain Cantagrel, Satveer K. Mahil, Marta Caprioli, Andrea M Seet, Samar Al Emadi, Philip Robinson, Claudia Diniz Lopes Marques, Ricardo Machado Xavier, Rebecca Grainger, Tiffany Y-T Hsu, Lindsay Jacobsohn, Adriana Maria Kakehasi, Paul Sufka, Milena A. Gianfrancesco, Alexander Pfeil, Jonathan Barker

Publikováno v: JAMA Network Open
Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect), Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) & COVID-19 Global Rheumatology Alliance 2021, ' Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19 ', JAMA Network Open, vol. 4, no. 10, e2129639 . https://doi.org/10.1001/jamanetworkopen.2021.29639
JAMA network open. American Medical Association

Key Points Question Is receipt of tumor necrosis factor (TNF) inhibitor monotherapy at the time of COVID-19 diagnosis associated with adverse COVID-19 outcomes compared with other treatment regimens among patients with immune-mediated inflammatory di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a66bf543761f55bfb3be5fe8e33c225b
https://doi.org/10.1001/jamanetworkopen.2021.29639